psoriatic arthritis, and axial spondyloarthritis. With expanding indications and competitive efficacy, it continues to gain market share against rivals. DelveInsight’s “TALTZ Market Size ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

“Psoriatic arthritis is a complex disease involving ... 23-targeting Skyrizi (risankizumab), Eli Lilly’s IL-17 blocker Taltz (ixekizumab) and Pfizer's oral JAK inhibitor Xeljanz (tofacitinib ...

IL-17 inhibitors included secukinumab (Cosentyx), ixekizumab (Taltz), and brodalumab (Siliq ... et al "Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment ...

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support ...

HSBC lowered its target price for Sun Pharmaceuticals to ₹2,000, maintaining a ’buy’ rating. The revision reflects clinical ...

and Taltz (ixekizumab) in Phase 3 trials. These therapies all utilize monthly maintenance dosing in PsO and psoriatic arthritis (PsA), except Bimzelx in PsO patients weighing <120 kg, where Q8W ...

and Taltz (ixekizumab) in Phase 3 trials. These therapies all utilize monthly maintenance dosing in PsO and psoriatic arthritis (PsA), except Bimzelx in PsO patients weighing 120 kg, where Q8W ...

Psoriasis was less likely to progress to psoriatic arthritis (PsA ... IL-17 inhibitors included secukinumab (Cosentyx), ixekizumab (Taltz), and brodalumab (Siliq). In the IL-23 inhibitor class ...